Arch Dermatol Res
May 2023
Background: Brentuximab vedotin (BV) has been approved for CD30-expressing cutaneous T-cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited.
Objectives: To evaluate the response and tolerance of BV in a cohort of patients with CTCL.
Eur J Cancer
October 2021